|
JPMorgan Partners JPMorgan Partners is a global partnership with over $30 billion in total capital under management. It is a leading provider of private equity and has closed over 1,800 individual transactions since its inception in 1984. JPMorgan Partners has more than 160 investment professionals in eleven offices throughout the world. Recent lead life sciences investments in Europe include Microscience, RiboTargets, Lorantis, and Renovo, and in the US include Eyetech, Myogen, and Apothogen. JPMorgan Partners’ primary limited partner is J.P. Morgan Chase & Co. (NYSE:JPM), one of the largest financial institutions in the United States. For additional information, please visit our website at www.jpmorganpartners.com |
 |
|
Katan Associates Katan is a globally based advisory services organization that provides a variety of integrated and interdisciplinary business and financial services to developing, knowledge-based growth and biotechnology companies. Our clients will share in the diversified operational, financial and strategic experiences that Katan’s senior management has gained in their various roles with numerous companies. We have a proven track record of adding significant value to formative-stage companies, providing management, financial, business development and strategic basis for a company’s growth and success. Katan assists in any of the following areas:
|
 |
|
Macquarie Bank Macquarie provides specialist investment, advisory and financial services in select markets around the world, with over 4,500 people located in 16 countries. The Macquarie Group comprises Macquarie Bank, Australia’s leading investment bank, and its worldwide affiliated entities. Macquarie Bank is a leading provider of a full range of investment banking, financial markets and retail financial services in Australia. It ranks as one of Australia’s top 25 companies by market capitalisation and has reported successive years of record profits and consistent growth since 1992. Comprehensive and integrated advisory services are offered to corporate clients in Australia and internationally, including advice on mergers and acquisitions, divestments, privatisations, corporate restructuring, capital raising, debt and risk management. Macquarie’s Health and Biotechnology team provides the full range of investment banking services to companies in this sector at all stages of their development and is an active investor in early stage life sciences companies in the region. For further information, please contact John Knights, Peter Hanley or John O’Connell on (+61 2) 8232 3333. |
 |
|
Morgan Lewis Morgan Lewis, with a team of over 1,100 lawyers in 13 offices worldwide, is a fully integrated, multipractice law firm that serves global clients. For over a century, Morgan Lewis has represented leading life sciences, technology, energy, securities and media companies, as well as multinational financial services and investment banking organizations. Our life sciences practice encompasses over 150 lawyers, life sciences PhDs, scientists and technical specialists. We understand the scientific, business and regulatory issues facing our approximately 500 clients in the life sciences industry who range from research hospitals and scientific institutions to the world’s largest pharmaceutical and medical device companies to startup biotechnology companies. As diverse as our clients are, they face common issues. Our practice is uniquely situated to focus on a full range of business activities, from litigation to research relationships to intellectual property protection and business disputes and counseling, as well as key capabilities, including healthcare, patents and patent litigation, and antitrust and extensive experience in mergers, acquisitions and capital raising. |
 |